Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial

Hansel Gómez-Arámbula, Antonio Hidalgo-Hurtado, Rosaura Rodríguez-Flores, Ana-María González-Amaro, Arturo Garrocho-Rangel, Amaury Pozos-Guillén, Hansel Gómez-Arámbula, Antonio Hidalgo-Hurtado, Rosaura Rodríguez-Flores, Ana-María González-Amaro, Arturo Garrocho-Rangel, Amaury Pozos-Guillén

Abstract

Background: The aim of this study was to compare the days of hospitalization length between patients treated with Moxifloxacin with that of patients treated with a Clindamycin/Ceftriaxone combination and additionally, to isolate and identify the oral pathogens involved in orofacial odontogenic infections.

Material and methods: A pilot-controlled-clinical-trial was carried out on hospitalized patients with cervicofacial odontogenic abscesses or cellulitis, who were randomly asigned to two study groups: 1) patients who received Moxifloxacin, and 2) patients receiving Clindamycin/Ceftriaxone combination. Infiltrate samples were collected through transdermic or transmucosal punction and later cultured on a media specific for aerobic and anaerobic microorganisms. Mean hospitalization duration in days until hospital discharge and susceptibility assessment in rates were established.

Results: Mean hospitalization time in days of patients treated with Moxifloxacin was 7.0 ± 1.6 days, while in the Clindamycin/Ceftriaxone group, this was 8.4 ± 1.8 days, although significant difference could not be demonstrated (p=0.074). A total of 43 strains were isolated, all of these Gram-positive. These strains appeared to be highly sensitive to Moxifloxacin (97.5%) and Ceftriaxone (92.5%).

Conclusions: Moxifloxacin and Ceftriaxone appear to be potential convenient and rational alternatives to traditional antibiotics, for treating severe odontogenic infections, in conjunction with surgical extraoral incision, debridement, and drainage.

Key words: Orofacial odontogenic infections, antimicrobial susceptibility, antimicrobial resistance.

Figures

Figure 1
Figure 1
Description of study patient evolution according to Consolidated Standards of Reporting Trials (CONSORT) criteria.

References

    1. Singh M, Kambalimath DH, Gupta KC. Management of odontogenic space infection with microbiology study. J Maxillofac Oral Surg. 2014;13:133–9.
    1. Cachovan G, Nergiz I, Thuss U, Siefert HM, Sobottka I, Oral O. Penetration of moxifloxacin into rat mandibular bone and soft tissue. Acta Odontol Scand. 2009;67:182–6.
    1. Walia IS, Borle RM, Mehendiratta D, Yadav AO. Microbiology and antibiotic sensitivity of head and neck space infections of odontogenic origin. J Maxillofac Oral Surg. 2014;13:16–21.
    1. Sobottka I, Wegscheider K, Balzer L, Böger RH, Hallier O, Giersdorf I. Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. Antimicrob Agents Chemother. 2012;56:2565–9.
    1. Limeres J, Tomás I, Álvarez M, Diz P. Empirical antimicrobial therapy for odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:263–4.
    1. Al-Nawas B1, Walter C, Morbach T, Seitner N, Siegel E, Maeurer M. Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. Eur J Clin Microbiol Infect Dis. 2009;28:75–82.
    1. Swift JQ, Gulden WS. Antibiotic therapy-managing odontogenic infections. Dent Clin N Am. 2002;46:623–33.
    1. Kuriyama T, Karasawa T, Nakagawa K, Saiki Y, Yamamoto E, Nakamura S. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:600–8.
    1. Sobottka I, Cachovan G, Stürenburg E, Ahlers MO, Laufs R, Platzer U. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother. 2002;46:4019–21.
    1. Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections. Int J Antimicrob Agents. 2002;20:451–6.
    1. Tomás I, Alvarez M, Limeres J, Otero JL, Saavedra E, López-Meléndez C. In vitro activity of moxifloxacin compared with other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain. Oral Microbiol Immunol. 2004;19:331–5.
    1. Cachovan G, Böger RH, Giersdorf I, Hallier O, Streichert T, Haddad M. Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. Antimicrob Agents Chemother. 2011;55:1142–7.
    1. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.
    1. Heit JM, Stevens MR, Jeffords K. Comparison of ceftriaxone with penicillin for antibiotic prophylaxis for compound mandible fractures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:423–6.
    1. Brennan MT, Runyon MS, Batts JJ, Fox PC, Kent ML, Cox TL. Odontogenic signs and symptoms as predictors of odontogenic infection: a clinical trial. J Am Dent Assoc. 2006;137:62–6.
    1. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics. 1979;35:183–197.
    1. Midolo PD, Tumidge J, Lambert JR, Bell JM. Validation of a modified Kirby-Baur disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis. 1995;21:135–40.
    1. Performance standards for antimicrobial disks susceptibility. Approved Standard, 9th ed. Wayne, PA, USA: Clinical Laboratory Standards Institute (CLSI); 2006. pp. 1–76.
    1. Chunduri NS, Madasu K, Goteki VR, Karpe T, Reddy H. Evaluation of bacterial spectrum of orofacial infections and their antibiotic susceptibility. J Maxillofac Surg. 2012;2:46–50.
    1. Sepännen L, Lauhio A, Lindqvist C, Suuronen R, Ratemaa R. Analysis of systemic and local odontogenic infection complications infection complications requiring hospital care. J Infect. 2008;57:116–22.
    1. Warnke PH, Becker ST, Springer IN, Haerle F, Ullmann U, Russo PA. Penicillin compared with other advanced broad spectrum antibiotics regarding antibacterial activity against oral pathogens isolated from odontogenic abscesses. J Craniomaxillofac Surg 2008;36:462–7.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit